Partnerships
The NITD was set up as a public-private partnership between Novartis and the Singapore Economic Development Board in 2003.
The NITD is entirely dependent on the early formation of partnerships on a global scale, from early research activities such as target identification and high throughput screening, through later stages of the drug-development process.
Partnerships are also necessary for successful outreach to patients, and to make treatments available to developing countries under affordable conditions. NITD partnerships include:
Singapore Dengue Consortium
The Singapore Dengue Consortium consists of eleven organizations, including the NITD, focused on research into dengue fever. These organizations have signed a memorandum of understanding with the intention of exploring ways to better understand and manage the dengue fever infection. The other consortium members include the DSO National Laboratories, Duke-NUS Graduate Medical School Singapore, Experimental Therapeutics Centre, A*STAR, Genome Institute of Singapore, A*STAR, Institute of Molecular and Cell Biology, A*STAR, Nanyang Technological University, National Environment Agency, National Healthcare Group, National University of Singapore, and Singapore Health Services.
Discover more on the Singapore Dengue Consortium participants:
The Duke-NUS Graduate Medical School Singapore
The Experimental Therapeutics Centre, A*STAR
The Genome Institute of Singapore, A*STAR
The Institute of Molecular and Cell Biology, A*STAR
The Nanyang Technological University
The National Environment Agency
The National University of Singapore
Global Alliance for TB Drug Development
The Global Alliance for TB Drug Development is a public-private partnership driven to halt the rise and reverse the spread of tuberculosis. Novartis and the Global TB Alliance just triggered a five-year research collaboration designed to yield new medicines for TB, including drug-resistant TB.
Discover more on the Global Alliance for TB Drug Development
NITD - Eijkman Institute - Hasanuddin University Clinical Research Initiative (NEHCRI)
The NITD has a partnership with the Eijkman Institute and Hasanuddin University to conduct clinical research into dengue fever, tuberculosis and malaria that aims to strengthen translational research in these areas. The establishment of the NEHCRI will provide NITD researchers direct access to hospitals and patients in a real-life context on a daily basis.
Discover more on NEHCRI partners:
Grant from Wellcome Trust, Singapore Economic Development Board and Medicines for Malaria Venture for malaria research
The partnership will allocate USD 20 million to discover the next generation of malaria drugs focusing on the development of a one-dose cure for Plasmodium falciparum, the most dangerous form of malaria, and a curative modality for Plasmodium vivax, the most frequent and widely distributed cause of malaria. The NITD will manage the program and conduct research jointly with several institutions including the Genomics Institute of the Novartis Research Foundation, the Swiss Tropical Institute and the Biomedical Primate Research Center.
Discover more on Grant for Welcome Trust partners:
The Genomics Institute of the Novartis Research Foundation
The Biomedical Primate Research Center
Grant from the Grand Challenges for Global Health Initiative, funded by the Bill and Melinda Gates Foundation and Wellcome Trust
Together with Imperial College as the lead grantee, NITD and 10 other collaborators received a USD 20 million grant to discover new targets for latent and persistent tuberculosis infection. The aim is to deliver final candidate compounds for pre-clinical development for these targets.
Advisory board
Research at the NITD is overseen by a scientific advisory board that includes:
- Professor Karl-Heinz Altmann
Professor of Pharmaceutical Biology
Institute of Pharmaceutical Sciences, ETH Zurich, Switzerland - Professor Sydney Brenner
Nobel Laureate
The Salk Institute, San Diego, USA - Professor Duane J. Gubler
Director, Asia-Pacific Institute for Tropical Medicine and Infectious Diseases
University of Hawaii, Honolulu, USA - Professor Barbara Imperiali
Class of 1922 Professor of Chemistry and Professor of Biology,
Massachusetts Institute of Technology, Cambridge, USA - Professor John D McKinney
Professor of Bacteriology
School of Life Sciences-FSV
Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland - Professor Marcel Tanner
Director, Swiss Tropical Institute
Basel, Switzerland - Professor Rolf Zinkernagel
Nobel Laureate
Head, Institute for Experimental Immunology
University of Zurich, Switzerland
Tackling poverty
Poverty and health problems are global and more complex than ever. More aid can be leveraged to help poor countries.
Find out how
(149 KB)
Review
